Evidence map›Paper›PMID 29089887›Full record

ArticleFrontiers in aging neuroscience2017

Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway.

Tatsunori Oguchi, Ran Ono, Mayumi Tsuji, Hidenobu Shozawa, Masayuki Somei, Manami Inagaki, Yukiko Mori, Taro Yasumoto, Kenjiro Ono, Yuji Kiuchi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 66 citations in OpenAlex.

  1. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019
    Trial
  2. Article
  3. Boosting Neurogenesis as a Strategy in Treating Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Drug repurposing for neurodegenerative diseases using Zebrafish behavioral profiles.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. miR-204-3p/Nox4 Mediates Memory Deficits in a Mouse Model of Alzheimer's Disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tatsunori OguchiDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Ran OnoDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Mayumi TsujiDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Hidenobu ShozawaDepartment of Internal Medicine, Division of Neurology, School of Medicine, Showa University, Tokyo, Japan.
Masayuki SomeiDepartment of Anesthesiology, Showa University Koto Toyosu Hospital, Tokyo, Japan.
Manami InagakiDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Yukiko MoriDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Taro YasumotoDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Kenjiro OnoDepartment of Internal Medicine, Division of Neurology, School of Medicine, Showa University, Tokyo, Japan.
Yuji KiuchiDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Showa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a slowly progressive form of dementia, characterized by memory impairment and cognitive dysfunction. AD is mainly characterized by the deposition of amyloid β (Aβ) plaques and intracellular neurofibrillary tangles in the brain, along with neuronal degeneration and high levels of oxidative stress. Cilostazol (CSZ) was recently found to suppress the progression of cognitive decline in patients with stable AD receiving acetylcholinesterase inhibitors. This present study aimed to clarify the mechanism by which CSZ protects neurons from degeneration associated with Aβ(1-42). We used Aβ(1-42) to induce neurotoxicity in human neuroblastoma SH-SY5Y cells. Cells were pretreated with CSZ before co-treatment with Aβ. To evaluate the effect of CSZ on oxidative stress, we examined levels of reactive oxygen species (ROS), nicotinamide adenine dinucleotide phosphate oxidase (Nox) activity, mRNA expression of NOX4, and Cu/Zn-Superoxide Dismutase (SOD), as well as apoptosis biomarkers [MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), caspase-3 and -9 activities and staining of annexin V]. We also assayed the activity of mitogen-activated protein kinases (MAPK): p38 MAPK and extracellular signal-regulated kinase1/2 (ERK1/2), and biomarkers of mitochondrial function (Bcl-2 and Bax), and cyclic adenosine monophosphate response element-binding protein (CREB). Aβ-induced oxidative stress (ROS, NOX4 activity, and expression of NOX mRNA), caspase activation (caspase-3 and -9), and p38 MAPK phosphorylation were suppressed by co-treatment with CSZ, but not by ERK1/2 activation. In addition, pretreatment with CSZ suppressed Aβ-induced apoptosis and increased cell viability via suppression of Bax (a proapoptotic protein), upregulation of Bcl-2 (an antiapoptotic protein) and Cu/Zn-SOD (a superoxide scavenging enzyme), and phosphorylation of CREB. These findings suggested that CSZ could counteract neurotoxicity through multiple mechanisms, one mechanism involving the attenuation of oxidative stress by suppressing NOX activity and Nox mRNA expression in Aβ-induced neurotoxicity and another involving the anti-neurotoxic effect via the ERK1/2/phosphorylated CREB pathway.

Indexed as

Alzheimer’s diseaseamyloid βapoptosiscilostazolMAPKNADPH oxidaseneurotoxicityoxidative stress

Identifiers

PMID29089887
PMCPMC5651005
OpenAlexW2767106718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.